RSU 1069

Known as: RSU-1069 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1984-2014
051019842014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
We have investigated the cross-sensitivity of a number of cell lines to three different classes of bioreductive drugs under both… (More)
  • table I
  • figure I
  • table II
  • figure 2
  • figure 3
Is this relevant?
1989
1989
The influence of altered tumour oxygenation on the responses to radiation and/or bioreductive 2-nitroimidazole compounds was… (More)
Is this relevant?
1987
1987
The effect of the vasodilator hydralazine on both the tumor and systemic toxicity of RSU-1069 has been evaluated in C57B1 mice… (More)
Is this relevant?
1986
1986
A series of nitroimidazoles containing aziridine and alkyl-substituted aziridine functions has been synthesized. The 2… (More)
Is this relevant?
1986
1986
RSU-1069 combines an aziridine function with a 2-nitroimidazole and has been reported to exhibit extraordinary radiosensitization… (More)
Is this relevant?
1986
1986
It is known that many solid animal tumours have a lower oxygenation level than most normal tissues and, in addition, that this… (More)
  • figure 1
  • figure 2
  • figure 5
  • figure 3
  • figure 6
Is this relevant?
1986
1986
The mixed-function radiosensitizer RSU-1069 and its analogues possess both alkylating and electron-affinic properties, and have… (More)
Is this relevant?
1986
1986
RSU-1069 is one of a group of compounds of particular interest in radiobiology, since it combines the nitroimidazole ring with a… (More)
Is this relevant?
1986
1986
Strand breakage of plasmid DNA by parent and radiation-reduced RSU-1069 (2.0-8.0 mmol dm-3) has been measured in air over 4 hr at… (More)
Is this relevant?
1986
1986
The radiosensitizing and cytotoxic properties of the drug RSU-1069, (1-(2-nitro-1-imidazolyl)-3-(1-aziridino)-2-propanol) a 2… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?